We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Congress Weighs Value Of Pediatric Exclusivity

Law360 (June 7, 2007, 12:00 AM EDT) -- Legislation in Congress would lower the amount of market exclusivity that drug makers are awarded for pediatric testing of their drugs, a development the U.S. Food and Drug Administration opposes.

A provision of the U.S. Senate drug user fee bill, S.1082, would lower pediatric exclusivity from six months to three months if the drug is considered a blockbuster, or one that made over $1 billion in annual sales.

The bill has already passed in the Senate. The U.S. House of Representatives is considering how to approach...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.